Posted by Michael Wonder on 04 Sep 2023
PHARMAC widens access to treatment for life-long bleeding disorder, severe haemophilia A
4 September 2023 - PHARMAC has confirmed it is widening access to emicizumab (Hemlibra) for the treatment of people with severe haemophilia A without factor VIII inhibitors.
In addition to the widened access to emicizumab for the treatment of severe haemophilia A, PHARMAC is also widening access to ocrelizumab for primary progressive multiple sclerosis. Widened access for both treatments will start from 1 October 2023.
